RECENT ADVANCES IN MITIGATING BIOFILMS ON MEDICAL DEVICES
Author:
Adriana Cogo Malgueiro Lirio, Daniela Dal Molim Ghisleni, Dinesh Kumar Chellappan2, Kamal Dua, Terezinha de Jesus Andreoli Pinto*
Published Date:
2024-03-15
Keywords:
Biofilm, microbial control, medical devices, implants, surface, coating.
Abstract:
Poor prognosis, patient distress, increased morbidity/mortality, antibiotic resistance and increased financial burden to patients and healthcare systems are some of the consequences of biofilm-related infections that arise from contaminated medical devices. The complex tri-dimensional architectural intricacy of biofilms has become an inevitable challenge to existing treatment options. It has also largely affected the development of in vitro models that help in the study of biofilm composition, formation, prevention, and therapeutic targets for eradicating biofilms. Newer biofilm models which were recently developed, enjoyed limited success in mitigating the limitations encountered by the traditional simpler models. More in-depth studies are needed to consider them relevant and accurate. Implants are generally considered as high risk medical devices, as they are exposed to patients’ tissues for a longer duration of time. Implants are reported to represent 65% of total implant-related infections. Because of this reason, most studies reported in the literature have focused on biofilm-related infections from implants. Considering the severity of such infections and the difficulty in treatment, novel effective strategies revolving around biofilm prevention in medical devices are seen to be the urgent need of hour. Recent studies have shown that rough edged surfaces had the greatest cellular adhesion. In addition, certain types of material were found to be most susceptible to biofilm growth such as titanium alloy discs, polymethyl methacrylate (PMMA), polyethylene (UHMW-PE), stainless steel (SST), aluminum, hydroxyapatite (HA) and polyethylene (PE). Newly developed implant coating techniques and nanomedicine-based strategies are promisors to prevent biofilm occurrence, although risk-benefit concerns still need to be considered. Therefore, comprehensive studies are needed to address the existing limitations. There is also a need for innovative techniques that can test biocompatibility and efficiency of the products to ensure they are effective and safe to the patients.